Clinical Study Of The Soft Liver Cataplasm Treatment Of Primary Biliary Cirrhosis

Purpose:In Chinese medical theory of disease outside the rule developed under the guidance of traditional Chinese medicine treatment of soft cataplasm liver, liver fibrosis, the liver of soft poultice of primary biliary cirrhosis TGF-β1, MMP-1, TIMP-1 effect.Material and method: 60cases in Liaoning University Hospital of Traditional Chinese Medicine Division of Rheumatology in July 2010 to February 2011 met the diagnostic criteria of hospitalization in patients with cirrhosis were randomly divided into treatment by the Western group based therapy plus soft liver cataplasm The treatment group of 30 patients in the control group that is the basis of the treatment group of 30 Western patients, the treatment group of 30 patients, 24 males and 6 females; mean age: (50±2.1) years, mean disease duration: (12±6) months Among them, 4 patients with liver cirrhosis, primary biliary cirrhosis, 25 cases of alcoholic cirrhosis in 1 case. Control group of 30 patients, 23 cases of male patients, 7 were female patients, mean age (45±3) years, mean disease duration (7±3. 2) months, 3 cases of alcoholic cirrhosis, primary biliary cirrhosis 26 cases, hepatitis C cirrhosis in 1 case. Month course of treatment, patients were observed before and after treatment and the therapeutic effect of TGFβ-1, MMP-1, TIMP-1 changes. Groups were compared using analysis of variance. TGF-β1, MMP-1, TIMP-1 detection were by radioimmunoassay.Results:1. TCM clinical efficacy evaluation: control group: 4 cases were markedly effective in 14 cases, 12 cases, the total effective rate: 60%. Treatment group: 12 cases markedly effective in 10 cases, 8 cases, total effective rate: 73.3% (p <0.05). 2. Traditional quantitative points: the treatment group: before treatment: 22.9±2.6, after treatment: 10.8±2.4, change the value: 12.1±0.2; control group: before treatment: 24.0±2.0, after treatment: 23.0±2.0, the change is: 1.0. The treatment group than the control group, were significantly different (p <0.05). 3.Liverfibrosis:treament of liver fibrosis TGF-β1,MMP-1,TIMP-1changes in values were:10.4±2.6(ng/ml), -168.3±(-51.6),60.0±(-2.8); control group: TGF-β1, MMP-1, TIMP-1 changes in values were: 14.1±4.3, -168.2±(-50.6), 83.8±29.6. Comparison of two groups of three indicators were statistically significant difference (p <0.05).Conclusion:Ruangan cataplasm by transdermal delivery, and by the Liver and Gallbladder points in the role of the projection surface so that the active ingredients of drugs to disease are, in Chinese medicine to quantify liver fibrosis score and improvement, the treatment group than the control group And soft cataplasm no significant liver toxicity, demonstrating a soft treatment of liver cirrhosis cataplasm effective security method is worthy of promotion and application, so that it can to relieve pain more sclerosis patients. Generate a new therapeutic approach...